# A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

> **NCT06692738** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 880 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Rilvegostomig
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT06692738
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2029-02-05
- **Final completion:** 2029-10-08
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06692738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06692738, "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT06692738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*